---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000077"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:43:24.859247+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed

## Summary
- Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.
- Cash & equivalents $665.2M; 2026 cash burn guidance <$390M, runway into early 2028 without financing.
- REC-1245 (RBM39 degrader): No DLTs in 16 patients; well-tolerated with dose-dependent PK; dose escalation ongoing.
- REC-4881 (MEK1/2) in FAP: 43% median polyp burden reduction at Week 13; FDA engagement for registrational path begun.
- REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1 ENLYGHT study; reversible design to reduce platelet toxicity.

## SEC filing metadata
- accession: 0001601830-26-000077
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/0001601830-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/rxrx-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000077
- JSON: https://secwatch.observer/filing/0001601830-26-000077.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000077.txt

## Source-grounded claims
- claim_id: ad9a4bca2d17c99e13a01442623d05ba11d1e136
  claim: RECURSION PHARMACEUTICALS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
  evidence_excerpt: today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/0001601830-26-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.